@article {JacksonP4.429作者= {Carlayne杰克逊和Mamede de卡瓦略和安琪拉其全称和特里Heiman-Patterson和杰里米·Shefner和艾米Wohltman和安德鲁·a·沃尔夫},title ={测量在肌萎缩性脊髓侧索硬化症:疾病进展缓慢的肺活量和ALSFRS-R措施之间的相关性的呼吸功能(P4.429)},体积={90}={15}补充数量,elocation-id = {P4.429} ={2018},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:确定之间的相关性缓慢肺活量(SVC)和症状以修改后的肌萎缩性脊髓侧索硬化症(ALS)功能评定量表(ALSFRS-R)更好地描述SVC在肌萎缩性侧索硬化症的临床决策。首页背景:不存在建立ALS疾病进展的标志;然而,残疾和死亡通常源于呼吸肌肉功能下降,这表明呼吸道措施应该用于预测疾病进展。SVC已被证明是等价于广泛应用用力肺活量和是一个机动的病人更容易执行。设计/方法:使审判的安慰剂组(NCT01281189)进行了分析。皮尔逊相关系数(r)是用来评估预测SVC百分比之间的关系和大量的个人ALSFRS-R呼吸子域项目,总ALSFRS-R呼吸子域名,。结果:预测百分比SVC与呼吸困难明显相关(r = .3611;p \ <。),端坐呼吸(r = .3230;p \ <。),呼吸衰竭(r = .3496;p \ <。),呼吸子域名的分数(r = .4262;p \ <。)。ALSFRS-R总分之间的相关性和\ %预测SVC是最高的(r = .5519;p \ <。)。 Percent of SVC variance explained by dyspnea, orthopnea, respiratory insufficiency, and the entire respiratory subdomain was 13\%, 10\%, 12\%, and 18\%, respectively. Thirty percent of SVC variance was explained by overall ALSFRS-R score.Conclusions: SVC is significantly correlated with individual ALSFRS-R respiratory symptoms; however, each item and the overall respiratory subdomain score accounted for only a small percentage of SVC variance. The ALSFRS-R is often used to follow disease progression, and these results suggest that changes in SVC are associated with a considerable amount of change in ALSFRS-R over time. However, the relatively low correlations observed stress the importance of directly measuring pulmonary function repeatedly when making clinical decisions.Study Supported by: Cytokinetics, Inc.Disclosure: Dr. Jackson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Mitsubishi Tanabe Pharma America: Medical Advisory Board and Speaker{\textquoteright}s Bureau, Cytokinetics {\textemdash} Medical Advisory Board, Avanir {\textemdash} Speaker{\textquoteright}s Bureau, GLG {\textemdash} Consulting services, Stonebridge Pharmaceuticals {\textemdash} Medical Advisory Board. Dr. Jackson has received research support from Cytokinetics, Flex Pharma, Neuraltus. Dr. de Carvalho has received research support from Cytokinetics Inc, a grant given to my Institute to explore the correlation between SVC and FVC in ALS and to investigate to predictor value of SVC in ALS patient survival. Dr. Genge has received research support from Dr Genge is an investigator for AB Sciences, Alexion, AL-S Pharma, Baxter, Bioblast, Biogen, CSL Behring, Cytokinetics, Genzyme, Grifols, Ionis, Novartis, Roche, Sanofi, and UCB. Dr. Heiman-Patterson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Mitsubishi Tanabe Pharma America: Medical Advisory Board, Cytokinetics {\textemdash} Medical Advisory Board. Dr. Shefner has nothing to disclose. Dr. Wohltman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with I am an employee of Cytokinetics. Dr. Wolff has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Yes, I am a paid employee of Cytokinetics, Inc. Dr. Wolff holds stock and/or stock options in Yes, my shares and options to purchase in Cytokinetics, Inc., are \> $10,000 in value., which sponsored research in which Dr. Wolff was involved as an investigator. Dr. Wolff holds stock and/or stock options in Yes, my shares and options to purchase in Cytokinetics, Inc., are \> $10,000 in value. Dr. Wolff has received research support from Yes, I am a paid employee of Cytokinetics, Inc.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/90/15_Supplement/P4.429}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }